An interventional study of FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100) in Congenital Diaphragmatic Hernia, sponsored by Dr Erin Perrone. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Dr Erin Perrone · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States — 24 open to participants now, 28 under way, 2 of them phase 3. Hernias, Diaphragmatic, Congenital · United States.
Among the 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States, this one is the 34th largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2021, is one of 28 with no phase, and was the 24th registered.
86 studies on the registry are indexed under Hernias, Diaphragmatic, Congenital; 39 are open to participants now.
Browse Hernias, Diaphragmatic, Congenital studies →24 of the 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States are open now. Recruiting first, the newest first:
Mauro H. Schenone · Sites in United States
Ages 18–50 · Women only
Dr Erin Perrone · Sites in United States
Ages 18+
Vincent Duron · Sites in United States
Ages 18+
The University of Texas Health Science Center, Houston · Sites in United States
Ages 0 mo–1 mo
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 18–50 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 32 Hernias, Diaphragmatic, Congenital studies recruiting now, 16 (50%) set no upper age limit and 16 (50%) stop at 75 or younger; 13 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4 is below the median of 30 across 62 interventional studies indexed under Hernias, Diaphragmatic, Congenital.
Median enrollment 21 across the 36 interventional studies, 51 across the 8 observational. Of the 14 that completed or were terminated, 5 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 45 has an industry lead sponsor. The 10 most frequent:
Dr Erin Perrone is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Dr Erin Perrone has 2 studies filed under Hernias, Diaphragmatic, Congenital — fewer than ten, so there is no comparison to draw.
2 of the studies in Hernias, Diaphragmatic, Congenital with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04583644Hanmin LeePilot Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) in Severe Left Congenital Diaphragmatic Hernia (CDH) | 2027-04 |
| NCT00950118Columbia UniversityDiaphragmatic Hernia Research & Exploration, Advancing Molecular Science | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single site pilot trial to assess the feasibility and safety of treating severe CDH with Fetal Endoscopic Tracheal Occlusion with the Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100) at Michigan Medicine. The study will enroll pregnant women that meet study criteria. Participants will have placement of FETO between gestational age at 27 weeks plus 0 days and 29 weeks 6 days. The timing for removal of FETO will ideally be between 34 weeks 0 days and 34 weeks and 6 days but ultimately decided by the Fetal Diagnosis and Treatment Center at Michigan Medicine.
This study requires that study participants live within 30 miles of the Von Voigtlander Women's Hospital and C.S. Mott Children's Hospital in order to maintain weekly follow up appointments while the balloon is in place and up to delivery. Additionally, there are lifestyle considerations where participants would be unable to carry on normal daily activities including exercise and sexual intercourse, not be able to work the remainder of the pregnancy, as well as have a support person that is available to stay with such as a spouse, friend, partner, parent.
This study has concluded and the second FETO trial (NCT07577414) has begun enrolling participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Meets psychosocial criteria
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A balloon will be placed in the airway of the fetus during the FETO procedure.
Device: FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100)
This will take place between gestation of 27w0d - 29w6d. The balloon will be removed at approximately 34 weeks gestation.
Number of Participants With Successful Placement of the Goldballoon Detachable Balloon (GOLDBAL2) at Gestational Age 27 Weeks Zero Days (27w0d) to 29 Weeks and 6 Days (29w6d) Gestation.
Success will be defined as completion with direct visual placement above the carina and confirmation on ultrasound done during the procedure.
Time frame: Between 27 weeks 0 days and 29 week 6 days of gestation, within 1 week of enrollment
Number of Participants With Successful Retrieval of the GOLDBAL2
This will ideally occur around the 34th week of gestation and have the balloon removed prior to delivery. Alternatively, it could occur on placental bypass.
Time frame: Removal prior to delivery approximately 34 weeks of gestation (up to approximately 8 weeks post enrollment) or at delivery on placental bypass (up to approximately 14 weeks post enrollment)
Change in Observed to Expected Total Fetal Lung Volume (o/e TFLV) on Prenatal Magnetic Resonance Imaging (MRI)
Fetal MRI done prior to balloon placement and again done at approximately 2 weeks of balloon retrieval. Observed to expected total fetal lung volume (o/e TFLV) is the percentage of lung volume a fetus has compared to the expected lung volume for a fetus at the same gestational age. It is calculated by dividing the observed TFLV by the expected TFLV and multiplying by 100 to get a percent. This outcome measure is the median change in o/e TFLV between the MRIs.
Time frame: baseline (prior to balloon placement), approximately 2 weeks after balloon retrieval (approximately 11 weeks post enrollment)
Change in Fetal Lung Growth
Fetal ultrasounds will be done weekly while the balloon is in place. Fetal lung growth will be calculated as the difference between the observed to expected Lung to Head Ratio (o/e LHR) pre-balloon placement and the o/e LHR immediately prior to balloon removal. O/e LHR uses the area of the lung opposite of the diaphragmatic hernia divided by head circumference to get a lung to head ratio. The observed to expected lung to head ratio is the lung to head ratio divided by the expected lung to head ratio at that gestational age multiplied by 100 to get a percent. This outcome measure describes the change in o/e LHR.
Time frame: baseline (before balloon placement), immediately prior to balloon removal (up to approximately 14 weeks post enrollment)
Gestational Age at Delivery
Time frame: At the time of delivery (up to approximately 14 weeks post enrollment)
Survival of Infant to Hospital Discharge or 180 Days After Hospitalized
This will be measured after the infant is delivered to hospital discharge or analyzed for survival at 180 days for those still hospitalized at that time point.
Time frame: Discharge from hospital or up to 180 days in the hospital (up to approximately 40 weeks post enrollment)
Number of Participants With Maternal Complications
Complications during pregnancy, and/or at delivery and follow-up to include; preterm labor, premature rupture of membranes (PROM), Preterm Premature Rupture of Membranes (PPROM), oligohydramnios, polyhydramnios, placental abruption, chorioamniotic separation, chorioamnionitis, and other infection. In results, patients who experience PPROM are also counted for PROM.
Time frame: up to 4-8 weeks postpartum (up to approximately 22 weeks post enrollment)
Patients were recruited at the Fetal Diagnosis and Treatment Center at Michigan Medicine.
| Milestone | FETO With GOLDBAL2 |
|---|---|
| Started | 4 |
| Completed | 4 |
| Not completed | 0 |
Success will be defined as completion with direct visual placement above the carina and confirmation on ultrasound done during the procedure.
| Participants | FETO With GOLDBAL2 |
|---|---|
| Number of Participants With Successful Placement of the Goldballoon Detachable Balloon (GOLDBAL2) at Gestational Age 27 Weeks Zero Days (27w0d) to 29 Weeks and 6 Days (29w6d) Gestation. | 4 |
This will ideally occur around the 34th week of gestation and have the balloon removed prior to delivery. Alternatively, it could occur on placental bypass.
| Participants | FETO With GOLDBAL2 |
|---|---|
| Successful Removal | 3 |
| Not Successful Removal | 1 |
Fetal MRI done prior to balloon placement and again done at approximately 2 weeks of balloon retrieval. Observed to expected total fetal lung volume (o/e TFLV) is the percentage of lung volume a fetus has compared to the expected lung volume for a fetus at the same gestational age. It is calculated by dividing the observed TFLV by the expected TFLV and multiplying by 100 to get a percent. This outcome measure is the median change in o/e TFLV between the MRIs.
| percent of expected lung volume | FETO With GOLDBAL2 |
|---|---|
| Change in Observed to Expected Total Fetal Lung Volume (o/e TFLV) on Prenatal Magnetic Resonance Imaging (MRI) | 13.75 (-3 to 31) |
Fetal ultrasounds will be done weekly while the balloon is in place. Fetal lung growth will be calculated as the difference between the observed to expected Lung to Head Ratio (o/e LHR) pre-balloon placement and the o/e LHR immediately prior to balloon removal. O/e LHR uses the area of the lung opposite of the diaphragmatic hernia divided by head circumference to get a lung to head ratio. The observed to expected lung to head ratio is the lung to head ratio divided by the expected lung to head ratio at that gestational age multiplied by 100 to get a percent. This outcome measure describes the change in o/e LHR.
| percent of expected lung to head ratio | FETO With GOLDBAL2 |
|---|---|
| Change in Fetal Lung Growth | 18.95 (8.6 to 24) |
| weeks gestational age | FETO With GOLDBAL2 |
|---|---|
| Gestational Age at Delivery | 33.857 (33.714 to 37.143) |
This will be measured after the infant is delivered to hospital discharge or analyzed for survival at 180 days for those still hospitalized at that time point.
| Participants | FETO With GOLDBAL2 |
|---|---|
| Infant survived to discharge or 180 days in hospital | 1 |
| Infant did not survive to discharge or 180 days in hospital | 3 |
Complications during pregnancy, and/or at delivery and follow-up to include; preterm labor, premature rupture of membranes (PROM), Preterm Premature Rupture of Membranes (PPROM), oligohydramnios, polyhydramnios, placental abruption, chorioamniotic separation, chorioamnionitis, and other infection. In results, patients who experience PPROM are also counted for PROM.
| Participants | FETO With GOLDBAL2 |
|---|---|
| Preterm Labor — Patients who had this complication | 3 |
| Preterm Labor — Patients who did not have this complication | 1 |
| Premature Rupture of Membranes (PROM) — Patients who had this complication | 2 |
| Premature Rupture of Membranes (PROM) — Patients who did not have this complication | 2 |
| Preterm Premature Rupture of Membranes (PPROM) — Patients who had this complication | 2 |
| Preterm Premature Rupture of Membranes (PPROM) — Patients who did not have this complication | 2 |
| Oligohydramnios — Patients who had this complication | 2 |
| Oligohydramnios — Patients who did not have this complication | 2 |
| Polyhydramnios — Patients who had this complication | 2 |
| Polyhydramnios — Patients who did not have this complication | 2 |
| Placental Abruption — Patients who had this complication | 0 |
| Placental Abruption — Patients who did not have this complication | 4 |
| Chorioamniotic Separation — Patients who had this complication | 3 |
| Chorioamniotic Separation — Patients who did not have this complication | 1 |
| Chorioamnionitis — Patients who had this complication | 2 |
| Chorioamnionitis — Patients who did not have this complication | 2 |
| Other Infection — Patients who had this complication | 0 |
| Other Infection — Patients who did not have this complication | 4 |
Collected over From enrollment to 30 days after delivery for fetus/baby. From enrollment to maternal follow up appointment at 4 to 8 weeks after delivery for mother (up to approximately 22 weeks post enrollment). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FETO With GOLDBAL2 - Mother | 0/4 (0%) | 3/4 (75%) | 4/4 (100%) |
| FETO With GOLDBAL2 - Fetus/Baby | 3/4 (75%) | 4/4 (100%) | 4/4 (100%) |
| Event | FETO With GOLDBAL2 - Mother | FETO With GOLDBAL2 - Fetus/Baby |
|---|---|---|
| Respiratory failure and complications due to CDH with pulmonary hypoplasiaCongenital, familial and genetic disorders | — | 4/4 |
| CDH associated hemodynamic instabilityCongenital, familial and genetic disorders | — | 4/4 |
| hypoxemiaBlood and lymphatic system disorders | — | 4/4 |
| Preterm BirthGeneral disorders | — | 3/4 |
| pulmonary hypertension or hypertensive crisis requiring treatmentRespiratory, thoracic and mediastinal disorders | — | 3/4 |
| Preterm contractions requiring hospital admissionPregnancy, puerperium and perinatal conditions | 2/4 | — |
| Use of ECMO and associated complicationsSurgical and medical procedures | — | 2/4 |
| C-section for non-reassuring fetal heart tones leading to preterm deliverySurgical and medical procedures | 1/4 | — |
| Cholelithiasis with gallbladder attacksGastrointestinal disorders | 1/4 | — |
| Mother reported decreased fetal movementPregnancy, puerperium and perinatal conditions | — | 1/4 |
| Event | FETO With GOLDBAL2 - Mother | FETO With GOLDBAL2 - Fetus/Baby |
|---|---|---|
| discomfort or skin separation at incision siteSurgical and medical procedures | 4/4 | — |
| uterine irritability abdominal pain, cramping, and/or contractionsPregnancy, puerperium and perinatal conditions | 4/4 | — |
| nausea with or without vomitingGeneral disorders | 4/4 | — |
| general CDH expected symptoms and comorbidities within the first 30 days of lifeCongenital, familial and genetic disorders | — | 4/4 |
| headacheGeneral disorders | 3/4 | — |
| amnioreductionSurgical and medical procedures | 3/4 | — |
| new ECHO anatomic findingCardiac disorders | — | 3/4 |
| epidural related symptoms including tenderness, pain, scant heme, and/or replacementSurgical and medical procedures | 2/4 | — |
| yeast infectionPregnancy, puerperium and perinatal conditions | 2/4 | — |
| incisional pain at c-section site with or without redness/tendernessPregnancy, puerperium and perinatal conditions | 2/4 | — |
4 participants enrolled with their fetuses. Each participant was carrying one fetus for a total of 8 participants analyzed.
| Age, Customized(Participants) | FETO With GOLDBAL2 |
|---|---|
| Participants aged 18 years and older | 4 |
| Sex/Gender, Customized(Participants) | FETO With GOLDBAL2 |
|---|---|
| Sex of Pregnant Participant — Female | 4 |
| Sex of Pregnant Participant — Male | 0 |
| Sex of Fetus — Female | 0 |
| Sex of Fetus — Male | 4 |
| Race (NIH/OMB)(Participants) | FETO With GOLDBAL2 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 3 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Ethnicity (NIH/OMB)(Participants) | FETO With GOLDBAL2 |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 4 |
| Unknown or Not Reported | 0 |
| Observed to Expected Total Fetal Lung Volume (o/e TFLV)(percent of expected lung volume) | FETO With GOLDBAL2 |
|---|---|
| Median | 20.75 (17 to 24) |
| Observed to Expected Lung to Head Ratio (o/e LHR)(percent of expected lung to head ratio) | FETO With GOLDBAL2 |
|---|---|
| Median | 20.5 (14.6 to 22) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2021 to primary completion in Aug 2025, 52 months.
Results were first posted in Nov 2026, 1 year 2 months after primary completion. A results delay was requested in May 2025.
Of 40 interventional studies with no phase under Hernias, Diaphragmatic, Congenital, half reached primary completion within 108 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 133. This study's 52 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hernias, Diaphragmatic, Congenital →
Dr Erin Perrone